Navigation Links
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
Date:3/9/2011

SAN DIEGO, March 9, 2011 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that new Guidelines were recently published in The Annals of Thoracic Surgery that include point-of-care testing for platelet reactivity as a new recommendation for preoperative patient assessment(1).

Coronary artery bypass graft (CABG) patients on antiplatelet drugs have an increased risk of excessive perioperative bleeding. Clopidogrel (Plavix®) is often discontinued for 5-7 days before surgery to reduce this bleeding risk. Due to the considerable variability in patient response to clopidogrel, the Guidelines recommend point-of-care testing to "identify clopidogrel non-responders, who are candidates for early operative coronary revascularization and who may not require a preoperative waiting period after clopidogrel discontinuation."

The VerifyNow P2Y12 Test allows clinicians to measure the actual level of platelet reactivity in patients who have taken P2Y12 inhibitors (e.g. Plavix) and who have discontinued them prior to surgery. By integrating this information with other clinical data, clinicians are able to make more informed decisions regarding a patient's treatment and surgery schedule in their efforts to minimize bleeding risk and maximize patient safety.

"As the Guidelines recommend, it is very important to know which patients are at risk of bleeding," stated Dr. Alex Zapolanski, Cardiac Surgery Director at The Valley Heart & Vascular Institute in Ridgewood, NJ. "We use the VerifyNow P2Y12 Test as a key piece of data to help us decide when a patient can be taken to surgery. We have found by incorporating the test into our practice that we have been able to reduce the average pre-surgical patient length of stay by 3 days, resulting in significant cost savings."

"Accumetrics applauds the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists for the inclusion of point-of-care platelet reactivity testing as a new recommendation in the Blood Conservation Guidelines to improve outcomes and patient safety," said Timothy I. Still, President and CEO of Accumetrics. "Cardiac surgery, interventional cardiology and clinical cardiology are all segments in the continuum of cardiovascular patient care where the VerifyNow System provides valuable data to healthcare professionals."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.(1)  Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, Fitzgerald DJ, Likosky DS, Shann KG. 2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg. 2011 Mar;91(3):944-82.About AccumetricsAccumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents.  Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis.  Effient is a registered trademark of Eli Lilly and Company.

CONTACT:Jakob JakobsenChandler Chicco Agency310-309-1003Jjakobsen@ccapr.com Timothy I. StillPresident and CEOAccumetrics858-404-8260press@accumetrics.com
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device
2. Pioneer® Surgical Announces New International Sales V.P.
3. Anesthesiologists Use Caldolor® To Provide Preemptive Pain Control for Surgical Patients at U.S. Medical Centers
4. Reportlinker Adds Global Computer Assisted Surgical (CAS) Systems Industry
5. Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11
6. Zimmer Showcases Newly Acquired Line of Surgical Power Tools at 2011 AAOS Annual Meeting
7. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler
8. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
9. Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer
10. CareFusion to Sell International Surgical Products Distribution Business to Medline for $130 Million
11. Surgical Information Systems Completes IHE North American Connectathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017   Divoti USA will ... to the standard of the latest FDA requirements, which stipulates new ... Anyone in need of Medical ID jewelry such as Medical ... are engraved in terms of the new FDA requirements ... Divoti offers this dark ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):